Edition:
United Kingdom

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

80.35EUR
11 Dec 2017
Change (% chg)

€-0.20 (-0.25%)
Prev Close
€80.55
Open
€80.80
Day's High
€81.00
Day's Low
€79.85
Volume
61,927
Avg. Vol
82,188
52-wk High
€82.10
52-wk Low
€51.35

Latest Key Developments (Source: Significant Developments)

DiaSorin Q3 net profit up at EUR 29.3‍​ mln, confirms 2017 guidance
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - DIASORIN SPA ::Q3 NET REVENUE EUR ‍​149.4 MILLION VERSUS EUR 147.0 MILLION YEAR AGO.Q3 NET PROFIT EUR 29.3‍​ MILLION VERSUS EUR 28.7 MILLION YEAR AGO.REAFFIRMS ITS FY'17 GUIDANCE‍​.  Full Article

DiaSorin launches test Liaison SHBG to diagnose androgen-related disorders
Tuesday, 23 May 2017 

May 23 (Reuters) - DIASORIN SPA ::LAUNCHES TEST LIAISON SHBG FOR DIAGNOSIS OF DISORDERS RELATED TO THE ANDROGEN HORMONES.SGHB, WHICH IS PRODUCED IN LIVER, IS INVOLVED IN TRANSPORT OF SEX STEROIDS, SUCH AS DIHYDROTESTOSTERONE, TESTOSTERONE AND ESTRADIOL, IN BLOOD STREAM.ACCORDING TO GLOBAL DIAGNOSTIC MARKET STATISTICS, EUROPEAN INFERTILITY MARKET IS ESTIMATED AT 130 MILLION EUROS WITH SHBG ACCOUNTING FOR ABOUT 4%, EQUAL TO A VOLUME EXCEEDING 2.7 MILLION TESTS PER YEAR.  Full Article

DiaSorin and Beckman Coulter form partnership to bring hepatitis and HIV tests to U.S.
Tuesday, 30 Aug 2016 

DiaSorin SpA : DiaSorin and Beckman Coulter Diagnostics (Beckman Coulter) form strategic partnership to bring Liaison XL hepatitis and HIV products to the United States market . Will work together with Beckman Coulter to submit the products to food and drug administration (FDA) for approval and commercialization in the United States . To offer customers in the United States access to the line of hepatitis and HIV products that can be run on Liaison XL LAS connected to Beckman Coulter's automation solutions . DiaSorin will retain right to commercialize products on Liaison XL stand-alone systems in hospital labs where total laboratory automation (TLA) is not required .Estimates that total available market in the United States for these products, excluding blood bank testing, exceeds $500 million.  Full Article

U.S. HHS awards $2.6 mln to Diasorin group to develop Zika test
Monday, 22 Aug 2016 

U.S. Department of Health and Human Services : U.S. HHS Awards $2.6 Million To Diasorin Group To Develop Rapid, High Capacity Zika diagnostic laboratory test . Contract supports development of diagnostic test, manufacturing preparations,clinical trials that could support application for FDA clearance Further company coverage: [DIAS.MI] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

DiaSorin Q2 net profit up 12.0 pct to EUR 29.4 mln
Thursday, 4 Aug 2016 

DiaSorin SpA : Q2 net profit 29.4 million euros ($32.73 million), up 12.0 percent year on year . Q2 revenue 141.7 million euros versus 127.5 million euros a year ago . Revises upwards the previous guidance on revenues and EBITDA for 2016, excluding the additional contribution resulting from the recent acquisition of the Focus Diagnostics' business . FY 2016 revenues: sees growth between 6 percent and 7 percent at CER (Constant Exchange Rate) compared with 2015 (previous guidance: growth between 5 percent and 6 percent at CER) .FY 2016 EBITDA: sees growth equal to around 9 percent at CER compared with 2015 (previous guidance: growth equal to around 8 percent at CER).  Full Article

DiaSorin launches test Iam AML1-ETO for screening of acute myeloid leukemia
Thursday, 14 Jul 2016 

DiaSorin SpA : Launches Iam AML1-ETO, a test for the molecular screening of acute myeloid leukemia .Test detects the translocation of AML1-ETO, one of the genetic causes of acute myeloid leukemia.  Full Article

Diasorin launches new test for IgG to Helicobacter Pylori detection
Tuesday, 7 Jun 2016 

Diasorin Spa :Says launched the new LIAISON test for qualitative detection of IgG to Helicobacter Pylori in human serum.  Full Article

DiaSorin Q1 net profit rises to EUR 24.7 mln
Monday, 9 May 2016 

DiaSorin SpA : Q1 revenue 124.5 million euros ($141.69 million) versus 117.6 million euros a year ago . Q1 net profit 24.7 million euros versus 22.6 million euros a year ago . Confirms guidance for 2016 revenues .Raises 2016 EBITDA guidance: growth equal to about 8 percent at CER (Constant Exchange Rates) compared with 2015 (previous guidance: growth between 6 percent and 7 percent at CER).  Full Article

DiaSorin SpA to buy Focus Diagnostics immunodiagnostic and molecular diagnostic products business
Wednesday, 30 Mar 2016 

DiaSorin SpA:Enters agreement with Quest Diagnostics (Quest) to buy its Focus Diagnostics, Inc. immunodiagnostic and molecular diagnostic products business.Under the terms of the purchase agreement, DiaSorin will pay to Quest Diagnostics $300 million in cash for all the tangible and intangible assets of Focus Diagnostics used to develop manufacture and distribute its molecular diagnostic products.The acquisition does not include Quest's diagnostic information service laboratories currently operating under the Focus Diagnostics brand.The acquisition will be carried out by DiaSorin also through a newly created U.S. affiliate and it is expected to be completed in the second quarter 2016, subject to customary closing conditions.  Full Article

DiaSorin SpA proposes FY 2015 dividend
Wednesday, 9 Mar 2016 

DiaSorin SpA:‍Proposed cash dividend equal to 0.65 euro per share​.  Full Article

BRIEF-DiaSorin Q3 net profit up at EUR 29.3‍​ mln, confirms 2017 guidance

* Q3 NET REVENUE EUR ‍​149.4 MILLION VERSUS EUR 147.0 MILLION YEAR AGO